Pulmonary toxicities of tyrosine kinase inhibitors

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 11, 2011, Pages 824-836

  Peerzada, Maajid Mumta ^a   Spiro, Timothy P ^a   Daw, Hamed A ^a  

^a Fairview Hospital   (United States)

Author keywords

Pulmonary toxicities, tyrosine kinase inhibitors, interstitial lung disease, imatinib, erlotinib, gefitinib

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; BCR ABL PROTEIN; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FLUCONAZOLE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; METHYLPREDNISOLONE; MITOMYCIN; NAVELBINE; OXYGEN; PACLITAXEL; PLACEBO; PREDNISOLONE; PREDNISONE; STEROID;

ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ALLERGIC PNEUMONITIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTIFICIAL VENTILATION; CANCER CHEMOTHERAPY; CHILL; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COUGHING; DERMATOFIBROSARCOMA PROTUBERANS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; FIBROSING ALVEOLITIS; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC DISEASE; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPOXEMIA; HYPOXIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LEUKEMIA; LICHENOID ERUPTION; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TOXICITY; MACULOPAPULAR RASH; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PANCREAS CANCER; PANCREAS CARCINOMA; PHILADELPHIA 1 CHROMOSOME; PNEUMOTHORAX; PULMONARY HYPERTENSION; RADIATION PNEUMONIA; REVIEW; RHEUMATIC POLYMYALGIA; SYMPTOM; SYSTEMIC MAST CELL DISEASE; TREATMENT FAILURE; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; FUSION PROTEINS, BCR-ABL; HUMANS; LUNG DISEASES, INTERSTITIAL; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 82155181646     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Lin JT, Yeh KT, Fang HY, Chang CS. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate/ Leuk Lymphoma. 2006;47:1693-1695.
2. Akoun GM, Cadranel J, Rosenow EC 3rd. Bronchoalveolar lavage cell data in drug-induced pneumonitis. Allerg Immunol. 1991;23:245-252.
3. Bergeron A, Bergot E, Vilela G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002;20:4271-4272.
4. Rajda J, Pathak PD. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Division of hematology and oncology, Rochester General Hospital, Rochester, New York. Published online in Wiley Interscience (www.interscience.wiley.com). DOI:10.1002/ajh.20319.
5. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003;78:1578-1579.
6. Isshiki I, Yamaguchi K, Okamoto S. Interstitial pneumonitis during imatinib therapy. Br J Haematol. 2004;125:420.
7. Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis J Clin Oncol. 2003;78:3171-3173.
8. Seki N, Ito A, Watanabe K, et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med. 2007;46:1941-1942.
9. Yamasawa H, Sugiyama Y, Bando M, Ohno S. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration. 2008;75:350-354.
10. Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, et al. Interstitial pneumonia mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia. 2004;18:645-646.
11. Yazdi AS, Metzler G, Weyrauch S, et al. Lymphomatoid granulomatosis induced by imatinib-treatment. Arch Dermatol. 2007;143:1222-1223.
12. Bekkenk MW, Vermeer MH, Meijer CJ, et al. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood. 2003;102:4243.
13. Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell receptormediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473-2479.
14. Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg DA. Imatinibassociated pulmonary alveolar proteinosis Am J Med. 2003;115:674.
15. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
16. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20:1162-1164.
17. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics. 2000;20:1245-1259.
18. Sakai F, Noma S, Kurihara Y, et al. Leflunomide related lung injury in patients with rheumatoid arthritis: imaging features. Modern Rheumatol. 2005;15:173-179.
19. Liu V, White DA, Zakowski MF, et al. Pulmonary toxicity associated with erlotinib. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Chest. 2007;132:1042-1044.
20. Makris D, Scherpereel A, Copin MC, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer. 2007;7:150.
21. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10:461-466.
22. Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J. 2007;14:167-170.
23. Lind JS, Smit EF, Grünberg K, Senan S, Lagerwaard FJ. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. J Thorac Oncol. 2008;3:1050-1053.
24. Yoneda KY, Shelton DK, Beckett LA, Gandara DR Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:537-543.
25. Bach JP, Kiessling AM, Kleinhans A, et al. Pulmonary fibrosis in a patient treated with erlotinib. Onkologie. 2006;29:342-343.
26. Tarceva [product information]. Genentech, South San Francisco, CA; 2004.
27. Boeck S, Hausmann A, Reibke R, Schulz C, Heinemann V. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs. 2007;18:1109-1111.
28. Kubota K, Nishiwaki Y, Tamura T, et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol. 2008;3:1439-1445.
29. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med. 2005;353:123-132.
30. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-smallcell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol. 2006;23:161-170.
31. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. J Clin Oncol. 2005;23:5892-5899.
32. Tammaro KA, Baldwin PD, Lundberg AS. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharm Pract. 2005;11:127-130.
33. Dragovich T, Patnaik A, Rowinsky EK et al. A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies. Proc Am Soc Clin Oncol. 2003;22: Abstract 223.
34. Yamamoto N, Yamada Y, Shimoyama T, et al. A phase I study of erlotinib HCl in Japanese patients with various types of solid tumors. Proc Am Soc Clin Oncol 2003;22: Abstract 225.
35. Tan AR, Yang X, Berman A, et al. Evaluation of epidermal growth factor receptor signaling in tumor and skin biopsies after treatment with OSI-774 in patients with metastatic breast cancer. Proc Am Soc Clin Oncol. 2003;22:196.
36. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004;45:93-104.
37. Kris MG, Sandler A, Miller V. Cigarette smoking history predicts sensitivty to erlotinib: results of a phase II trial in patients with bronchoalveolar carcinoma (BAC). Proc Am Soc Clin Oncol. 2004;22: Abstract 7062.
38. Johnson BE, Lucca J, Rabin M. Preliminary results from a phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol. 2004;22: Abstract 7080.
39. Dragovich T, Huberman M, Von Hoff DD, et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol. 2007;60:295-303.
40. Mori M, Nakagawa M, Fujikawa T, et al. Simultaneous bilateral spontaneous pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple lung metastases. Intern Med. 2005;44:862-864.
41. Umemura S, Kishino D, Tabata M, et al. Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer. Intern Med. 2005;44:979-982.
42. Shih YN, Chiu CH, Tsai CM, Perng RP. Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer. J Chin Med Assoc. 2005;68:183-186.
43. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J. 2003;22:179-181.
44. Seto T, Seki N, Uematsu K, et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology. 2006;11:113-116.
45. Sumpter K, Congleton J, Harper-Wynne C, O'Brien M. Severe acute interstitial pneumonia and gefitinib. Lung Cancer. 2004;43:367-368.
46. Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs. 2003;14:665-668.
47. Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y. Acute gefitinibinduced pneumonitis. Int J Clin Oncol. 2004;9:406-409.
48. Müller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer. 2004;91:S24-30. Review.
49. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer. 2004;91:S18-23.
50. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137-139.
51. Park HS, Lee HJ, Im JG, et al. Gefitinib-induced pneumonitis in non-small cell lung cancer: radiological and clinical findings in five patients. Clin Imaging. 2007;31:306-312.
52. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8:303-306.
53. Madtes DK, Rubenfeld G, Klima LD, et al. Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1998;158:424-430.
54. Madtes DK, Busby HK, Strandjord TP, Clark JG. Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. Am J Respir Cell Mol Biol. 1994;11:540-551.
55. Hardie WD, Prows DR, Piljan-Gentle A, et al. Dose-related protection from nickel-induced lung injury in transgenic mice expressing human transforming growth factor-alpha. Am J Respir Cell Mol Biol. 2002;26:430-437.
56. Hardie WD, Prows DR, Leikauf GD, Korfhagen TR. Attenuation of acute lung injury in transgenic mice expressing human transforming growth factoralpha. Am J Physiol. 1999;77:L1045-1050.
57. Inomata S, Takahashi H, Nagata M, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs. 2004;15:461-467.
58. Kitajima H, Takahashi H, Harada K, et al. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology. 2006;11:217-220.
59. Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer. 2005;47:129-138.
60. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004;45:93-104.
61. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004;46:247-254.
62. Iressa [package insert]. AstraZeneca Pharmaceuticals. Wilmington, DE; November 2004.
63. Tarceva [package insert]. Genentech. South San Francisco, CA and OSI Pharmaceuticals, Melville, NY; 2004. 64. Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol. 2005;23:2423-2424.
64. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004;91:S3-10. Review.
65. Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:193-196.
66. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549-2556.
67. Hotta K, Kiura K, Tabata M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J. 2005;11:417-424.
68. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177:1348-1357.
69. Armour A. Gefitinib in advanced non-small cell lung cancer: clinical experience in patients of Asian origin. Asia Pac J Clin Oncol. 2007;3:66-78.
70. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004;45:93-104.
71. Kataoka K, Taniguchi H, Hasegawa Y, et al. Interstitial lung disease associated with gefitinib. Respir Med. 2006;100:698-704.
72. AstraZeneca. In-house data; result and discussion document concerning the prospective investigation on Iressa tablet 250 (special investigation). 2004.
73. Okamoto I, Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer. 2003;40:339-342.
74. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237-2246.
75. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815-3825.
76. Pallis AG, Mavroudis D, Androulakis N, et al. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer. 2003;40:301-317.
77. Forsythe B, Faulkner K. Safety and tolerability of gefitinib ('Iressa', ZD1839) in advanced NSCLC: overview of clinical experience Poster presented at: European Respiratory Society; September 27-October 1, 2003; Vienna, Austria. Poster number P327.